This application requests continued support for a training program in Cancer Biology that was begun in 1990. The program is designed to train predoctoral and postdoctoral fellows in the fundamentals of cancer research by participation in didactic courses, seminars and discussion groups, and in the performance of laboratory-based cancer research. The training program is integrated into the research programs of the Norris Cotton Cancer Center, thereby enhancing exposure to many facets of the disease. This is a multidisciplinary Training Program with 16 faculty draw n from six academic departments: Anesthesiology, Biochemistry, Engineering, Medicine, Microbiology, and Pharmacology and Toxicology. These faculty have an excellent training record, and are highly interactive both in their individual research efforts and through the programs of the Cancer Center. Predoctoral students are enrolled in one of four graduate programs: Cell and Molecular Biology (including Immunology), Chemistry, Engineering, and Pharmacology and Toxicology. Students will be recruited to the Training Grant after they have completed one or more years in these graduate programs, and have selected one of the Trainers as a mentor. This will allow their performance in first-year classes and research rotations to be used as additional evidence of their potential to succeed in a Ph.D. degree. Postdoctoral trainees will be engaged in research under the mentorship of a faculty adviser, but will have their research experience broadened by regular interactions with other faculty and fellows through conferences, seminars, and programmatic activities. Many of the trainees at both pre- and postdoctoral levels will engage in collaborative research with other listed trainers or with other members of the Cancer Center. This Training Program acts as an enhancement to the interactive environment that makes the Cancer Center a functional institution. Predoctoral trainees will generally be funded for three years, while postdoctoral trainees will be funded for two years. All trainees will be encouraged to obtain alternative extramural funding, thereby enhancing the overall number of trainees who can be supported. This mechanism also facilitates the recruiting of minority applicants as there is a more frequent turnover of positions, and hence funds can be assigned to any qualified minority as soon as we are able to interest him/her in the program. 2 T32 CA09658-11A1 3 Alan R. Eastman, Ph.D.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009658-12
Application #
6605897
Study Section
Subcommittee G - Education (NCI)
Program Officer
Gorelic, Lester S
Project Start
1991-07-01
Project End
2007-06-30
Budget Start
2003-08-25
Budget End
2004-06-30
Support Year
12
Fiscal Year
2003
Total Cost
$374,567
Indirect Cost
Name
Dartmouth College
Department
Pharmacology
Type
Schools of Medicine
DUNS #
041027822
City
Hanover
State
NH
Country
United States
Zip Code
03755
Jenkins, Molly H; Brinckerhoff, Constance E; Mullins, David W (2015) CXCR3 signaling in BRAFWT melanoma increases IL-8 expression and tumorigenicity. PLoS One 10:e0121140
Jenkins, Molly H; Steinberg, Shannon M; Alexander, Matthew P et al. (2014) Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032. Pigment Cell Melanoma Res 27:495-501
Busch, Alexander M; Galimberti, Fabrizio; Nehls, Kristen E et al. (2014) All-trans-retinoic acid antagonizes the Hedgehog pathway by inducing patched. Cancer Biol Ther 15:463-72
Norris, A M; Gore, A; Balboni, A et al. (2013) AGR2 is a SMAD4-suppressible gene that modulates MUC1 levels and promotes the initiation and progression of pancreatic intraepithelial neoplasia. Oncogene 32:3867-76
Busch, Alexander M; Johnson, Kevin C; Stan, Radu V et al. (2013) Evidence for tankyrases as antineoplastic targets in lung cancer. BMC Cancer 13:211
Balboni, Amanda L; Hutchinson, Justine A; DeCastro, Andrew J et al. (2013) ?Np63?-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells. Cancer Res 73:1020-30
Macari, Elizabeth R; Schaeffer, Emily K; West, Rachel J et al. (2013) Simvastatin and t-butylhydroquinone suppress KLF1 and BCL11A gene expression and additively increase fetal hemoglobin in primary human erythroid cells. Blood 121:830-9
Montano, Ryan; Chung, Injae; Garner, Kristen M et al. (2012) Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Mol Cancer Ther 11:427-38
Galimberti, Fabrizio; Busch, Alexander M; Chinyengetere, Fadzai et al. (2012) Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations. Int J Oncol 41:1751-61
Bates, Darcy J P; Salerni, Bethany L; Lowrey, Christopher H et al. (2011) Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis. Cancer Biol Ther 12:314-25

Showing the most recent 10 out of 67 publications